Neoantigenics, Inc.
  • Founded: 2012
  • CEO: Brian A. Pollok, Ph.D.
  • Size of Facility: 400 sq ft
  • Company Size: 3
  • Funding Source: Grants (e.g. SBIR, CRCF, CIT), Investor Funded, Venture Captital/Private Equity
  • Development Stage: Pre-clinical

Neoantigenics is a pre-clinical stage company focused on developing oncology theranostics (therapeutic plus diagnostic) products, founded on the novel science around oocyte (egg)-associated cancer proteins (“neoantigens”) discovered at the University of Virginia. These neoantigens are uniquely expressed in a wide range of urogenital tract cancers – ovarian, uterine, bladder and renal cancers – as well as certain other cancers such as aggressive stages of pancreatic cancer, many head-and-neck cancers, lung cancer, breast cancer and some leukemias.